ClinicalTrials.gg
CompletedNCT02985216Updated Jan 16, 2019

Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

A Phase 3 interventional study of YHD1119 and Lyrica in Peripheral Neuropathic Pain, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-16.

Sponsored by Yuhan Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Enrollment
2nd of 50
371 · median 109
Started
2017
with 1 other
Phase 3
18 of 50
1 open now
Registered
34th of 50
by date
Lead sponsor
2 of 50
Yuhan Corporation

Among the 50 studies testing pregabalin in Neuralgia, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 18 in phase 3, and was the 34th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Active-Controlled, Multi-center, Phase 3 Trial to Compare the Safety and Efficacy between YHD1119 and Pregabalin in Patients with Peripheral Neuropathic Pain

03

Conditions studied

  • Peripheral Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • ≤ 9.5% diabetes mellitus patients with pain over 6 months in Diabetic Peripheral Neuropathy or postherpetic Neuralgia patients at least 3 months pain after diagnosis of skin rash due to herpes zooster

Exclusion criteria

Exclusion Criteria:

  • Have Brittle diabetes mellitus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    YHD1119

    YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150\~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.

    Drug: YHD1119

  • Active comparator
    Lyrica

    Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150\~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.

    Drug: Lyrica

Interventions

  • YHD1119 150mg, PO YHD1119 300mg, PO YHD1119 600mg, PO

    Also known as: Pregabalin

  • DrugLyrica

    Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO

    Also known as: Pregabalin

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS)

    Time frame: Baseline, Day 85

Secondary outcomes

  1. Change From Baseline in Mean Pain Score on the Daily Pain Rating Scale (DPRS)

    Time frame: Day 1, 8, 15, 22, 29, 57, 85

  2. Mean Pain Score on the Daily Pain Rating Scale at each visit

    Time frame: Day 1, 8, 15, 22, 29, 57, 85

  3. Patients proportion of reduction over 30% in Mean Pain Score from Baseline

    Time frame: Day 1, 8, 15, 22, 29, 57, 85

  4. Change of duration-modification from baseline in Mean Pain Score on the Daily Pain Rating Scale (DPRS)

    Time frame: Day 1, 8, 15, 22, 29, 57, 85

  5. Patient Global Impression of Change (PGIC)

    Time frame: Day 85

  6. Clinical Global Impression of Change (CGIC)

    Time frame: Day 85

  7. SF-12 (Short form-12)

    Time frame: Baseline, Day 85

  8. C-SSRS (Columbia Suicide Severity Rating Scale)

    Time frame: Baseline, Day 8, 29, 85

07

Study locations

1 site
  • Yong Chul Kim
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Apr 2018, 14 months.

Of 33 phase 3 interventional studies under Neuralgia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2016
First posted
Dec 7, 2016
StartActual
Feb 7, 2017
Primary completionActual
Apr 27, 2018
CompletionActual
May 2, 2018
Last update
Jan 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02985216
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Dec 7, 2016
Start date
Feb 7, 2017
Primary completion
Apr 27, 2018
Completion
May 2, 2018
Last update
Jan 16, 2019

Study contacts

Yong Chul KIM, M.D.,Ph.D.
principal investigator · Seoul National University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion